Intracellular mitochondrial enzyme replacement therapy for heart and skeletalmyopathy in Barth Syndrome
细胞内线粒体酶替代疗法治疗巴特综合征的心脏和骨骼肌病
基本信息
- 批准号:9546783
- 负责人:
- 金额:$ 33.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-Methylglutaconic aciduria type 2AcyltransferaseAddressAffectAnimalsAntibody FormationApoptosisBiological AssayBloodCardiolipinsCardiomyopathiesCellsClinicalCyclic NeutropeniaDefectDiseaseDrug KineticsDrug or chemical Tissue DistributionEchocardiographyElectron TransportEndocytosisEngineeringEnzyme-Linked Immunosorbent AssayEnzymesFunctional disorderGenerationsGenesGenetic DiseasesHalf-LifeHeartHeart failureHumanImmature GranulocyteImmunofluorescence ImmunologicImmunohistochemistryImpairmentIn VitroIndividualInjectionsIntracellular TransportIntravenousLaboratoriesLeukocytesLifeLinkLysophospholipidsMeasuresMediatingMetabolicMetabolismMitochondriaMorphologyMusMuscleMuscle CellsMuscle functionMuscle hypotoniaMutationMyocardiumMyographyMyopathyNeutropeniaOperative Surgical ProceduresPathogenesisPathway interactionsPatientsPeptidesPerformancePermeabilityPhospholipidsPhysiologic pulsePlasmaPopulationProductionPropertyProteinsReactive Oxygen SpeciesReagentRecombinantsRespirationRoleSamplingSerumSkeletal MuscleTailTherapeuticTissuesTransacylaseVeinsconstrictioneffective therapyenzyme deficiencyenzyme replacement therapyexperimental studyimmunogenicityimprovedin vivoliquid chromatography mass spectrometrymiddle agemouse modelneutrophilnovelpharmacokinetic characteristicrespiratoryskeletaltreadmilluptake
项目摘要
Abstract: Intracellular mitochondrial enzyme replacement therapy for heart and skeletal
myopathy in Barth Syndrome
Barth Syndrome is an X-linked disorder resulting from defects in the gene encoding Tafazzin,
an acyltransferase that modifies cardiolipin to the tetralinoleoyl form and is essential for mitochondrial
respiration. The clinical manifestations of Barth Syndrome include muscular hypotonia,
cardiomyopathy and neutropenia. At present, no effective therapy exists for affected individuals. The
main issue that this project will address is whether an enzyme replacement strategy in which
recombinant tafazzin is linked to a cellular penetrating peptide can promote uptake into tafazzin-
deficient cells, restore cardiolipin remodeling, suppress abnormal production of mitochondrial reactive
oxygen species (ROS), restore normal mitochondrial respiration, improve heart and skeletal muscle
performance and improve neutropenia. This project will utilize a mouse model of Barth Syndrome
from Jackson laboratories and initial studies to characterize baseline function in heart and skeletal
muscle have been done. Other significant milestones include generation and purification of
recombinant tafazzin protein that has been modified to contain a cellular permeability peptide, along
with verification of its ability to enter cells and correct both cardiopin remodeling and mitochondrial
respiration defects in vitro and in live animals. Other project findings are that tafazzin-deficient
myocytes produce ROS at higher levels than control cells, and that exogenous tafazzin protein
suppresses this excess ROS generation. In this proposal, elucidation of mechanisms by which
recombinant tafazzin engineered for intracellular uptake can enter cells and correct the metabolic
defects in tafazzin-deficient cells or animals will facilitate understanding of whether this novel
recombinant tafazzin reagent can provide a treatment for cardiomyopathy, skeletal myopathy and
neutropenia in Barth Syndrome patients.
翻译后摘要:细胞内线粒体酶替代疗法的心脏和骨骼
Barth综合征肌病
巴斯综合征是一种X连锁疾病,由编码Tafazzin的基因缺陷引起,
一种酰基转移酶,将心磷脂修饰为四氢萘油酰形式,是线粒体
呼吸巴斯综合征的临床表现包括肌张力减退,
心肌病和中性粒细胞减少症。目前,对受影响的个人没有有效的治疗方法。的
该项目将解决的主要问题是,
与细胞穿透肽连接的重组tafazzin可促进tafazzin的摄取。
缺乏细胞,恢复心磷脂重塑,抑制线粒体反应性的异常产生,
氧物种(ROS),恢复正常的线粒体呼吸,改善心脏和骨骼肌
性能和改善中性粒细胞减少症。这个项目将利用巴斯综合征的小鼠模型
来自杰克逊实验室和初步研究,以表征心脏和骨骼的基线功能
肌肉已经完成了。其他重要的里程碑包括生成和纯化
一种重组tafazzin蛋白,其已被修饰为含有细胞渗透性肽,沿着
通过验证其进入细胞并纠正心肽重塑和线粒体的能力,
体外和活体动物的呼吸缺陷。其他项目的发现是,
肌细胞产生ROS的水平高于对照细胞,外源tafazzin蛋白
抑制这种过量的ROS产生。在这项建议中,阐明了
为细胞内摄取而设计的重组tafazzin可以进入细胞并纠正代谢紊乱,
他法津缺陷细胞或动物的缺陷将有助于理解这种新的
重组tafazzin试剂可提供心肌病、骨骼肌病和
Barth综合征患者的中性粒细胞减少症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL T CHIN其他文献
MICHAEL T CHIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL T CHIN', 18)}}的其他基金
Medical Scientist Training Program at Tufts University
塔夫茨大学医学科学家培训项目
- 批准号:
10626366 - 财政年份:2023
- 资助金额:
$ 33.69万 - 项目类别:
Functional assay development for tafazzin enzyme replacement candidate selection
用于 tafazzin 酶替代候选选择的功能测定开发
- 批准号:
10722856 - 财政年份:2021
- 资助金额:
$ 33.69万 - 项目类别:
Functional assay development for tafazzin enzyme replacement candidate selection
用于 tafazzin 酶替代候选选择的功能测定开发
- 批准号:
10405485 - 财政年份:2021
- 资助金额:
$ 33.69万 - 项目类别:
Functional assay development for tafazzin enzyme replacement candidate selection
用于 tafazzin 酶替代候选选择的功能测定开发
- 批准号:
10213565 - 财政年份:2021
- 资助金额:
$ 33.69万 - 项目类别:
In utero and early life diesel exposure, epigenetic modification and heart failur
子宫内和生命早期柴油暴露、表观遗传修饰和心力衰竭
- 批准号:
8899545 - 财政年份:2014
- 资助金额:
$ 33.69万 - 项目类别:
In utero and early life diesel exposure, epigenetic modification and heart failur
子宫内和生命早期柴油暴露、表观遗传修饰和心力衰竭
- 批准号:
8771328 - 财政年份:2014
- 资助金额:
$ 33.69万 - 项目类别:
Project 4: Myocardial Inury and Apoptosis with DE Exposure
项目 4:DE 暴露引起的心肌损伤和细胞凋亡
- 批准号:
8278532 - 财政年份:2011
- 资助金额:
$ 33.69万 - 项目类别:
Role of CHF1/Hey2 in Hypertrophy and Heart Failure
CHF1/Hey2 在肥厚和心力衰竭中的作用
- 批准号:
7597233 - 财政年份:2006
- 资助金额:
$ 33.69万 - 项目类别:
Role of CHF1/Hey2 in Hypertrophy and Heart Failure
CHF1/Hey2 在肥厚和心力衰竭中的作用
- 批准号:
7320073 - 财政年份:2006
- 资助金额:
$ 33.69万 - 项目类别:
Role of CHF1/Hey2 in Hypertrophy and Heart Failure
CHF1/Hey2 在肥厚和心力衰竭中的作用
- 批准号:
7216341 - 财政年份:2006
- 资助金额:
$ 33.69万 - 项目类别:
相似海外基金
Design of chemical probes for hedgehog acyltransferase
Hedgehog酰基转移酶化学探针的设计
- 批准号:
2600595 - 财政年份:2022
- 资助金额:
$ 33.69万 - 项目类别:
Studentship
Identification of the glycolytic enzyme palmitoyl acyltransferase
糖酵解酶棕榈酰酰基转移酶的鉴定
- 批准号:
571756-2022 - 财政年份:2022
- 资助金额:
$ 33.69万 - 项目类别:
University Undergraduate Student Research Awards
The role of LYCAT acyltransferase in phagocytosis and immune function
LYCAT酰基转移酶在吞噬作用和免疫功能中的作用
- 批准号:
564899-2021 - 财政年份:2021
- 资助金额:
$ 33.69万 - 项目类别:
University Undergraduate Student Research Awards
Targeting a Human Acyltransferase for Broad-Spectrum Antivirals
靶向人类酰基转移酶的广谱抗病毒药物
- 批准号:
10223496 - 财政年份:2021
- 资助金额:
$ 33.69万 - 项目类别:
Hedgehog acyltransferase : structure and function in health and disease
Hedgehog酰基转移酶:健康和疾病中的结构和功能
- 批准号:
BB/T01508X/1 - 财政年份:2020
- 资助金额:
$ 33.69万 - 项目类别:
Research Grant
Protein acyltransferase mediated S-palmitoylation and its Importance in Innate Immunity and Lipid Metabolism.
蛋白质酰基转移酶介导的 S-棕榈酰化及其在先天免疫和脂质代谢中的重要性。
- 批准号:
401169 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Operating Grants
Is transcription factor TEAD a missing protein lysine fatty acyltransferase?
转录因子 TEAD 是缺失的蛋白质赖氨酸脂肪酰基转移酶吗?
- 批准号:
19K22271 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Basic research on the development of therapeutic agents for Alzheimer's disease using Acyl-CoA:cholesterol acyltransferase inhibitor
利用酰基辅酶A:胆固醇酰基转移酶抑制剂开发阿尔茨海默病治疗剂的基础研究
- 批准号:
19K07093 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Defining the Molecular Architecture for Transmembrane Acylation by a Membrane Bound O-Acyltransferase
定义膜结合 O-酰基转移酶跨膜酰化的分子结构
- 批准号:
10246913 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
Characterization of Xenopus laevis DHAP acyltransferase
非洲爪蟾 DHAP 酰基转移酶的表征
- 批准号:
540689-2019 - 财政年份:2019
- 资助金额:
$ 33.69万 - 项目类别:
University Undergraduate Student Research Awards